Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Kissei Aims to Increase Sales, 1.3 Times by 2008: New Management Plan
May 26, 2003
- Annual Business Results
May 26, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 26, 2003
- Takara Bio to Promote Anti-cancer Immunotherapy via JV
May 26, 2003
- Annual Business Results
May 26, 2003
- WORLD NEWS IN BRIEF
May 26, 2003
- MPC to Create Marketing Subsidiary in Germany
May 19, 2003
- Health Promotion Law to Help Optimize Medical Spending: HSB Head
May 19, 2003
- Ethical Drug Sales Rose 3.7% in FY2002: CR&C Report
May 19, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
May 19, 2003
- BUSINESS NEWS IN BRIEF
May 19, 2003
- Yamanouchi's YM905 Effective for Pollakiuria: AUA Meeting
May 19, 2003
- NEW PRODUCTS
May 19, 2003
- Nu-Lotan Prevents Diabetes in Hypertensive Patients: Banyu Symposium
May 19, 2003
- Daiichi: R&D Spending, NHI Price Cuts Hit Sales, Profits
May 19, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
May 19, 2003
- Teijin: Pharma Sales Down 2.2% to \92.5 Bil.
May 19, 2003
- GENKY Stores to Go Public Next Month
May 19, 2003
- Freund: Sales Down 12.3%, Net Profits Down 94.7%
May 19, 2003
- DIAGNOSTIC NEWS IN BRIEF
May 19, 2003
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…